GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (STU:0P8) » Definitions » 14-Day RSI

Penumbra (STU:0P8) 14-Day RSI : 44.20 (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Penumbra 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-04), Penumbra's 14-Day RSI is 44.20.

The industry rank for Penumbra's 14-Day RSI or its related term are showing as below:

STU:0P8's 14-Day RSI is ranked better than
86.2% of 884 companies
in the Medical Devices & Instruments industry
Industry Median: 46.42 vs STU:0P8: 44.20

Competitive Comparison of Penumbra's 14-Day RSI

For the Medical Devices subindustry, Penumbra's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra's 14-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Penumbra's 14-Day RSI falls into.



Penumbra  (STU:0P8) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Penumbra  (STU:0P8) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Penumbra 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Penumbra's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra (STU:0P8) Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Penumbra (STU:0P8) Headlines

No Headlines